What are the opening hours?

Monday 8am - 5pm Tuesday 8am - 5pm Thursday 8am - 5pm Friday 8am - 5pm

Dr. Isreb- The Integrative Nephrologist, Vancouver, WA (2026)

04/09/2026

🦠🫘 Blog Highlight of the day: The Gut–Kidney Connection in Autoimmune Kidney Disease

The relationship between the gut microbiome and kidney health is becoming one of the most fascinating frontiers in nephrology.

Inside the gastrointestinal tract lives a complex immune network known as gut-associated lymphoid tissue (GALT). This system constantly communicates with the microbiome and helps the body distinguish between harmless microbes and potential threats.

When the gut barrier becomes disrupted—often called intestinal hyperpermeability or “leaky gut”—microbial fragments such as lipopolysaccharides (LPS) can cross into circulation.

These molecules activate immune sensors known as toll-like receptors (TLRs), which trigger inflammatory signaling pathways such as NF-κB and MAPK.

This cascade increases inflammatory cytokines like TNF-α and interleukins, potentially driving systemic immune activation.

Why does this matter for the kidneys?

Because the same immune receptors involved in gut signaling are also present in kidney tissue itself.

Activation of these pathways has been linked to several autoimmune kidney diseases, including:

• IgA nephropathy
• ANCA-associated vasculitis
• Systemic lupus erythematosus

In other words, disturbances in gut microbiome balance may help trigger immune responses that mistakenly target kidney tissue.

This raises important questions for both clinicians and patients:

Could restoring gut integrity help reduce autoimmune inflammation?
Should gut health be a routine part of managing autoimmune kidney disease?
And how much of systemic immune disease begins in the microbiome?

The emerging science of the gut–kidney axis suggests that kidney health may depend not only on what happens in the kidneys, but also on what happens in the gut.

What are your thoughts on the microbiome’s role in autoimmune diseases?

Let’s discuss 👇

Read the full blog here:

https://inkidney.com/gut-kidney-autoimmune/

04/08/2026

😴🫘 Study Highlight: Sleep Apnea May Cause Early Kidney Injury

Sleep apnea is often thought of as a sleep disorder.

But this large systematic review and meta-analysis of 26 studies involving over 4,300 participants suggests the effects may extend much deeper, reaching the kidneys long before traditional lab tests detect disease.

Researchers examined early kidney injury biomarkers in people with obstructive sleep apnea (OSA) who did not yet have diagnosed chronic kidney disease.

Compared with individuals without OSA, patients with sleep apnea had significantly higher levels of markers linked to early kidney stress and injury, including:

• 🧪 Microalbuminuria
• 🧪 Cystatin C
• 🧪 Urine albumin-to-creatinine ratio (uACR)
• 🧪 NGAL, a marker of tubular injury
• 🔥 Interleukin-18, an inflammatory cytokine associated with kidney damage

Even more interesting, the study found a dose–response relationship.

The more severe the sleep apnea, the higher these kidney injury biomarkers tended to be.
People with hypertension and severe OSA showed the strongest signals of early kidney stress.

This suggests that the repeated cycles of intermittent hypoxia, sympathetic activation, and inflammation seen in sleep apnea may begin damaging the kidneys long before eGFR declines.

Why this matters

These findings reinforce an emerging concept in nephrology:

Sleep apnea may be an early and modifiable driver of kidney injury.

Because markers like cystatin C and microalbuminuria are widely available, they may help clinicians detect subclinical kidney stress in patients with OSA and intervene earlier.

It also raises a broader question:

If sleep apnea can quietly stress the kidneys years before CKD appears, should screening for sleep disorders be part of kidney disease prevention?
Have you seen improvements in kidney markers after treating sleep apnea?

What are your thoughts about this study? Let us know in the comments👇

Read the study here: [https://www.sciencedirect.com/science/article/pii/S1389945725023639?via%3Dihub ]

04/07/2026

Most of kidney care begins at a stage when the disease is already well established.

We have made extraordinary progress in treating advanced kidney disease. Dialysis, transplantation, and pharmacologic therapies have transformed outcomes in ways that were unimaginable decades ago.

But much of what drives kidney disease develops long before patients reach nephrology care.

Metabolic dysfunction. Chronic stress. Environmental exposures. Lifestyle patterns. Genetic predisposition.

These are not peripheral factors. They are central to how kidney disease develops and progresses.

Yet in clinical practice, they are often addressed in isolation, if at all.

This raises a simple question:

👉 What would kidney care look like if we identified and addressed these drivers earlier and more systematically?

This is the gap that "Integrative Nephrology" aims to fill.

Not as an alternative to conventional care, but as an expansion of it.

04/06/2026

🔬 Study Highlight:

When Alkaline Phosphatase Fluctuates, CKD Outcomes Worsen

Alkaline phosphatase (ALP) is often checked in routine labs, but its role in kidney disease risk may be more important than many clinicians realize.

In a large retrospective cohort study of more than 14,000 patients with chronic kidney disease, researchers examined whether ALP levels and their variability over time predicted long-term outcomes.

The results were striking.

Patients with higher baseline ALP levels had a significantly greater risk of:

• Progression to end-stage kidney disease
• All-cause mortality

But the most interesting finding involved ALP variability.

Patients whose ALP levels fluctuated the most over time had markedly higher mortality risk compared with those whose ALP levels remained stable.

These relationships persisted even after adjusting for major comorbidities such as:

• Diabetes
• Hypertension
• Cardiovascular disease

In other words, ALP instability itself may signal underlying physiologic stress.
Possible mechanisms include:

• CKD-related mineral and bone disorder
• Vascular calcification
• Chronic inflammation
• Disturbed bone turnover

Why this matters

ALP is widely available, inexpensive, and already part of routine laboratory testing.

This study suggests that tracking ALP trends over time—rather than relying on a single value—may help identify CKD patients at higher risk of progression or mortality.

Sometimes the most valuable signals in medicine are already hiding in the labs we routinely measure.

Do you routinely monitor ALP trends in CKD patients?

Read the study here: [https://academic.oup.com/ckj/advance-article/doi/10.1093/ckj/sfag022/8456374]

04/05/2026

🧬🫘 Blog Highlight: Kidney Health Begins Before Birth

When we talk about risk factors for chronic kidney disease, we usually think about things that happen later in life:

• Hypertension
• Diabetes
• Obesity
• Medications or toxins

But one of the most important determinants of lifelong kidney health may actually be established before we are even born.

Each kidney contains about one million nephrons, the tiny filtering units responsible for clearing waste, balancing minerals, and regulating blood pressure.

Here’s the critical point:

Humans are born with their full lifetime supply of nephrons.

After birth, no new nephrons are created.

The number of nephrons present at birth is called nephron endowment, and it represents the functional kidney mass a person carries throughout life.

When nephron endowment is lower than normal, the remaining nephrons must work harder. Over time this can lead to:

• 🩸 Higher glomerular pressure
• 🫘 Hyperfiltration and accelerated nephron loss
• 📉 Greater risk of chronic kidney disease
• 📈 Higher risk of hypertension in adulthood

One of the strongest predictors of lower nephron endowment is low birth weight (

04/04/2026

🧂🫘 Blog Highlight: Potassium and Blood Pressure

For decades, hypertension advice has focused primarily on reducing sodium.

But an equally important part of the equation is often overlooked:

Increasing potassium intake.

Modern diets tend to be high in sodium and low in potassium, a combination strongly associated with elevated blood pressure and cardiovascular risk.

Research shows that potassium supports blood pressure control through several key physiologic mechanisms:

• 🧂 Promoting sodium excretion in the kidneys (natriuresis)
• 🧬 Modulating the RAAS system, reducing vasoconstriction signals
• 🩸 Improving vascular relaxation and lowering systemic resistance

In a recent dose–response meta-analysis of randomized trials, increasing potassium intake by about 50 mmol/day was associated with:

• 📉 ~5 mmHg reduction in systolic blood pressure
• 📉 ~3–4 mmHg reduction in diastolic blood pressure

These effects are especially pronounced in people with hypertension and are comparable to many lifestyle interventions.

But potassium’s influence may extend even further.

Emerging research suggests potassium-rich diets may also influence the gut microbiome, supporting beneficial microbes that produce short-chain fatty acids linked to healthier blood pressure regulation.

The bigger picture is this:

Blood pressure isn’t just about how much sodium we remove, but also how much potassium we restore.

What’s your experience with dietary potassium in blood pressure management?
Do you think clinicians talk about potassium enough when discussing hypertension?

What do you think? 👇

Read more here: [https://inkidney.com/potassium-intake-and-blood-pressure-control/]

04/04/2026

Astragalus has been used for centuries in traditional medicine, but modern nephrology research is now asking an important question:

Can astragalus help slow the progression of chronic kidney disease?

In our newest blog, we review the emerging research on Astragalus for Kidney Health, including its potential effects on:

• Proteinuria
• Inflammation and oxidative stress
• Fibrosis pathways involved in CKD progression
• Blood pressure and kidney function decline

Several studies suggest astragalus may improve markers such as creatinine clearance, eGFR trends, and proteinuria when used alongside standard care. In one recent randomized trial in patients with diabetic kidney disease, adding astragalus slowed the rate of kidney function decline compared with conventional therapy alone.

But the story is nuanced.

Much of the clinical literature remains heterogeneous, and many studies have limitations. Major nephrology guidelines also remind clinicians that herbal therapies must be evaluated carefully in CKD, where drug interactions, contamination risks, and dosing considerations matter.

The most reasonable interpretation today is cautious optimism.

Astragalus may influence several pathways involved in kidney disease including inflammatory signaling, oxidative stress, and fibrotic remodeling. That multi-pathway effect is one reason it continues to attract scientific attention.

But it is not a replacement for proven therapies such as blood pressure control, ACE inhibitors, SGLT2 inhibitors, or diabetes management.

The real question may be whether astragalus could become part of a broader integrative kidney care model in the future.

💬 What do you think?

Should botanicals like astragalus be studied more rigorously as adjunct therapies in CKD?
Have you encountered research or clinical experience with astragalus in kidney disease?

Read the full blog:

https://inkidney.com/astragalus-for-kidney-health/

04/03/2026

Still navigating glomerulonephritis? Let’s connect. 💬

📢 The Glomerulonephritis Protocol is still available — and it’s more than just a download. It’s a conversation starter.

From IgA nephropathy to Membranous nephropathy, this 40-page guide is packed with insights on how to evaluate, monitor, and manage autoimmune kidney disease—designed for both healthcare providers and patients who want more clarity and control.

🔍 What's inside:

Disease-specific evaluation strategies
Immune system pathways and testing
Treatment frameworks: conventional and integrative
Monitoring tips and red flags to watch for

🧠 Whether you're a clinician refining your approach or a patient trying to make sense of your labs, this protocol offers actionable knowledge.

💬 What’s been your biggest challenge managing glomerulonephritis—confusing test results? Medication side effects? Feeling unheard?

Let us know in the comments — your experience might help someone else.
Ready to go deeper?

🚀 Dive in NOW and enrich your knowledge!

🔗 Download here:

https://inkidney.com/product/the-glomerulonephritis-protocol/

04/02/2026

🚬🫘 Blog Highlight: Ni****ne Pouches and Kidney Health

Ni****ne pouches are increasingly marketed as “smoke-free” or “tobacco-free” alternatives to ci******es and va**ng.

And it’s true that removing combustion eliminates many toxic chemicals found in smoke.
But one important question remains:

What does ni****ne itself do to the kidneys?

Ni****ne is not biologically neutral. It is a pharmacologically active compound that influences several pathways closely linked to kidney disease progression.

Research shows ni****ne can:

• ⚡ Activate the sympathetic nervous system
• 🩸 Raise blood pressure and heart rate
• 🍬 Worsen insulin resistance
• 🧂 Increase RAAS signaling and sodium retention
• 🔥 Promote inflammation and oxidative stress in kidney tissue
• 🧬 Stimulate fibrotic pathways that contribute to kidney scarring

From a kidney physiology perspective, these changes can lead to:

• Reduced renal blood flow
• Increased glomerular pressure
• Endothelial dysfunction
• Faster progression of kidney injury in vulnerable individuals

This is especially relevant for people with:

• Chronic kidney disease
• Hypertension
• Diabetes or metabolic syndrome
• Elevated cardiovascular risk

Ni****ne pouches may represent harm reduction compared with smoking, but they are not metabolically or renally neutral.

The bigger question may not be “Are ni****ne pouches safer?”

It may be:

What happens when the body experiences chronic ni****ne exposure throughout the day?
Have you seen patients transition from ci******es to ni****ne pouches?
Do you think clinicians should be discussing the kidney risks of ni****ne exposure more openly?

Let us know below 👇

And if you want to read the blog with its references, you can find it here: [https://inkidney.com/ni****ne-pouches-and-kidney-health/]

****ne

04/01/2026

🧠🫘 Blog Highlight: Stress-Response Kidney Disease

When we talk about chronic kidney disease, we usually focus on blood pressure, diabetes, and medications.

But there is another driver of kidney injury that often goes unrecognized:

Chronic activation of the stress response.

Emerging research shows that persistent activation of the HPA axis and sympathetic nervous system can directly influence kidney physiology.

Over time, chronic stress can:

• 🧠 Disrupt cortisol rhythms
• ⚡ Activate the sympathetic nervous system
• 🧂 Increase RAAS signaling and sodium retention
• 🩸 Raise blood pressure and glomerular pressure
• 🔥 Increase inflammation and oxidative stress
• 🫘 Accelerate CKD progression

This is part of what I describe as stress-response kidney disease.

The kidneys are among the most densely innervated organs in the body, meaning signals from the brain can rapidly change renal blood flow, renin release, and sodium handling.
At the same time, chronic stress often reduces vagal tone, weakening the body’s natural anti-inflammatory and recovery systems.

This autonomic imbalance can lead to:

• Higher blood pressure variability
• Poor sleep quality
• Increased inflammatory signaling
• Reduced physiologic resilience

The encouraging part is that these pathways are modifiable.

Interventions that improve autonomic balance may help protect kidney health, including:

• Slow breathing and HRV training
• Meditation and mindfulness
• Yoga or tai chi
• Nature exposure
• Practices that strengthen vagal tone

Stress management is not simply wellness advice.

It may be a physiologic strategy for protecting kidney function.

Have you noticed stress affecting your blood pressure, sleep, or overall health?

Tell us below 👇

And if you want to read the blog, here is the link: [https://inkidney.com/stress-response-kidney-disease/]

04/01/2026

A question that kept coming up in clinical practice:

Why do we wait until kidney disease is advanced before we intervene more comprehensively?

Many of the drivers of kidney disease—metabolic health, stress physiology, environmental exposures, and lifestyle factors—are present long before labs begin to change.

But these domains are often addressed separately, rather than within a unified clinical framework.

This question led to the development of “Integrative Nephrology”.

Now entering production.

More to come.

03/31/2026

Most people don’t realize that many common kidney drugs—such as ACE inhibitors, ARBs, diuretics, and statins—can deplete your body of essential nutrients, including zinc, magnesium, CoQ10, and vitamin B12.

These deficiencies don’t just cause fatigue—they can increase inflammation, weaken the heart, and accelerate kidney decline.

👉 For instance:

🔹ACE inhibitors may cause zinc loss and raise potassium dangerously high.
🔹Statins deplete CoQ10 and selenium, increasing muscle and heart risk.
🔹Metformin can quietly rob you of vitamin B12.

💬 It raises a critical question:

If medications protect one pathway while harming another, are we missing the bigger picture of kidney health?
Should routine nutrient monitoring be a standard part of CKD medication management?
Or are we still treating organs in isolation instead of systems in balance?

Share your thoughts below 👇

Read more on the blog [link in bio]

https://inkidney.com/kidney-medications-nutrients/

Dr. Isreb- The Integrative Nephrologist

04/09/2026

04/08/2026

04/07/2026

04/06/2026

04/05/2026

04/04/2026

04/04/2026

04/03/2026

04/02/2026

04/01/2026

04/01/2026

03/31/2026

Address

Opening Hours

Telephone

Website

Alerts

Contact The Practice

Shortcuts

Share

Category

Monday	8am - 5pm
Tuesday	8am - 5pm
Thursday	8am - 5pm
Friday	8am - 5pm